Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 4,516 matching trials from the live ClinicalTrials.gov search.
Filters: Lexington, Kentucky Clear all
Active, not recruiting Phase 3 Interventional Results available

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Interventions
Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhanced DPP-GLB to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.

NCT04757519
View directory record Official record
Conditions
Diabetes
Interventions
DPP-GLB Standard, DPP-GLB Enhanced
Behavioral
Lead sponsor
Lovoria Williams
Other
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
21
States / cities
Frankfort, Kentucky • Lexington, Kentucky • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

NCT00578175
View directory record Official record
Conditions
Varicella, Rubella, Mumps, Measles
Interventions
Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 14 Months
Enrollment
1,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
141
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

NCT04432831
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab, Sham Procedure
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
119
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

Lesinurad and Allopurinol Combination Extension Study in Gout

NCT01808131
View directory record Official record
Conditions
Gout
Interventions
Lesinurad
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Pinson, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Not applicable Interventional

Treatment of Muscle Weakness in Critically Ill Patients

NCT02247895
View directory record Official record
Conditions
Critical Illness, Respiratory Failure, Myopathy, Weakness
Interventions
Sham Treatment, Electrical stimulation
Device
Lead sponsor
Gerald Supinski
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

NCT00592839
View directory record Official record
Conditions
Nocturnal Vasomotor Symptoms
Interventions
SCE-B, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
17
States / cities
Anaheim, California • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

NCT02937701
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 710, Infliximab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

NCT00679939
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
21
States / cities
Tucson, Arizona • Huntington Park, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional

Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00016939
View directory record Official record
Conditions
Kidney Cancer
Interventions
alvocidib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 25, 2026, 10:41 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT03343977
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
docetaxel 50mg/m2, docetaxel 75mg/m2
Drug
Lead sponsor
Peng Wang, MD PhD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

NCT00002707
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, Tamoxifen
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Enrollment
2,411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
134
States / cities
Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 115 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Results available

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

NCT04608409
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Lapatinib and Paclitaxel
Drug
Lead sponsor
Frederick R. Ueland, M.D.
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

NCT03391765
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12, Placebo solution for IV infusion on Day 15
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 25, 2026, 10:41 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)

NCT04770064
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
High-dose/short-duration Fisetin, Low-dose/sustained-duration Fisetin, Oral placebo capsule
Drug · Other
Lead sponsor
Austin V Stone
Other
Eligibility
35 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia

NCT03893630
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Acetylsalicylic Acid 81 mg, Acetylsalicylic Acid 162 mg, Control
Drug · Other
Lead sponsor
John O'Brien, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Phase 2 Interventional Results available

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

NCT02899728
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Carboplatin, Cediranib, Cediranib Maleate, Cisplatin, Etoposide, Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Pasadena, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

NCT00085709
View directory record Official record
Conditions
Leukemia
Interventions
gemtuzumab ozogamicin, observation, Cytosine arabinoside, Daunomycin
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 60 Years
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
255
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 161 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

NCT00543400
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
M118, Unfractionated Heparin
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
19 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
37
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
MK-1045, Rituximab, Rituximab biosimilar, Bendamustine, Cyclophosphamide, Vincristine, Prednisone, Prednisolone, Doxorubicin Hydrochloride
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
5
States / cities
Duarte, California • Lexington, Kentucky • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting Not applicable Interventional

tDCS and Urge in BFRBs

NCT07019571
View directory record Official record
Conditions
Repetitive Compulsive Behavior
Interventions
Wireless Multichannel Transcranial Current Stimulator (tDCS), Cue exposure, Boredom induction
Device · Behavioral
Lead sponsor
Gopalkumar Rakesh
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT05761171
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Month to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

NCT00364871
View directory record Official record
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 25, 2026, 10:41 AM EDT